Columbia Technology Ventures
CNS/Neurology
Search text
Active Filters
Roger Lefort PhD
1 result
(0.02 seconds)
This technology provides a pharmacological approach for increasing the levels of a E3 ubiquitin protein ligase in neurons to treat synaptic dysfunction and loss in neurodegenerative diseases, as Alzheimer’s disease (AD).